Younger Age at Brain Tumor Diagnosis Portends Poor Emotional Outcome

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 15 No 8
Volume 15
Issue 8

Childhood survivors of brain tumors who were diagnosed at age 10 or younger have worse depressive symptomatology and social skills and lower feelings of self-worth than their counterparts who were diagnosed as pre-teens or teenagers

AMELIA ISLAND, Florida—Childhood survivors of brain tumors who were diagnosed at age 10 or younger have worse depressive symptomatology and social skills and lower feelings of self-worth than their counterparts who were diagnosed as pre-teens or teenagers, Fiona S.M. Schulte said at the American Psychosocial Oncology Society Third Annual Conference (abstract P6-2). This finding goes counter to previously held assumptions that younger children are immune from the emotional effects of such a devastating diagnosis, said Ms. Schulte, a PhD student in the Department of Psychology at the Hospital for Sick Children, University of Toronto.

Perception of Self-Worth

Ms. Schulte and her supervisor, Maru E.C. Barrera, MD, evaluated 58 survivors of pediatric brain tumors (aged 8 to 19 years), 7 years, on average, after completion of their treatment. Overall, as the children's perception of their self-worth and personal social skills increased, their depression scores decreased. "This was what you would expect," Ms. Schulte said. However, children who were diagnosed before age 10 had significantly higher depression scores than those diagnosed as preadolescents (age 11 to 13) or adolescents (age 14 to 17). This younger cohort also rated themselves as having lower social skills, compared to the older cohorts.

"Older age at diagnosis and high self-worth may serve as protective factors for perceptions of social skills and depressive symptoms," Ms. Schulte concluded. "These younger children are an important group to target from the beginning with interventions to help them with their social skills and their depression."

Recent Videos
According to John Henson, MD, “What we need are better treatments to control the [brain] tumor once it’s detected.”
Surgery and radiation chemotherapy can affect immunotherapy’s ability to target tumor cells in the nervous system, according to John Henson, MD.
Sonia Jain, PhD, stated that depatuxizumab mafodotin, ABBV-221, and ABBV-321 were 3 of the most prominent ADCs in EGFR-amplified glioblastoma.
Results showed no “deleterious reactions” with chlorotoxin-directed cellular therapy in a small cohort of patients with recurrent glioblastoma.
A novel CAR T-cell therapy may bind with more avidity, rather than affinity, to glioblastoma cells, said Michael Barish, PhD.
Using chlorotoxin as a targeting element may bind to more glioblastoma cells than other targeting entities, according to Michael Barish, PhD.
Historical standards for H3 K27M-mutant diffuse midline glioma treatment may harm healthy central nervous system cells, according to Ashley L. Sumrall, MD.
Dordaviprone was recommended at a dose of 625 mg orally once weekly for adults, and the recommended dosage is based on body weight for pediatric patients.
Extended follow-up for individuals with H3 K27M-mutated diffuse midline glioma may help explain the duration of response across patient subgroups.